Inspire Medical Systems, Inc. to Report Third Quarter 2022 Financial Results on November 1, 2022

Rhea-AI Summary

Inspire Medical Systems (NYSE: INSP) will announce its Q3 2022 financial results on November 1, following the market's close. Management will hold a conference call at 5:00 p.m. ET to discuss these results and recent business developments. Interested parties can register for the call via a provided link and access a live webcast on Inspire's Investor Relations page. Inspire specializes in minimally invasive solutions for obstructive sleep apnea, featuring its FDA-approved neurostimulation therapy.

Positive

• FDA-approved neurostimulation technology for sleep apnea treatment.
• Upcoming Q3 2022 earnings call may indicate financial and operational growth.

Negative

• None.

MINNEAPOLIS, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the third quarter 2022 after the close of trading on Tuesday, November 1. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

To access the call, please use the following link: Inspire's Q3 2022 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. 

A simultaneous webcast of the call will be accessible via the Investor Relations page of the Inspire’s website at www.inspiresleep.com. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Following the call, a replay will be available on the Company's Investor Relations website approximately two hours after the event and archived on the site for two weeks.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443

FAQ

When will Inspire Medical Systems release its Q3 2022 financial results?

Inspire Medical Systems will release its Q3 2022 financial results on November 1, 2022.

What time will the Inspire Medical Systems earnings call take place?

The earnings call will take place at 5:00 p.m. Eastern Time on November 1, 2022.

How can I access the Inspire Medical Systems earnings call?

You can access the earnings call by registering through a provided link in the press release.

What is the primary focus of Inspire Medical Systems?

Inspire Medical Systems focuses on innovative solutions for obstructive sleep apnea, including FDA-approved neurostimulation therapy.